Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody

The combined therapeutic potential of an immunocytokine designed to deliver IL-12 to the necrotic regions of solid tumors with an anti-PD-L1 antibody that disrupts the immunosuppressive PD-1/PD-L1 axis yielded a combinatorial benefit in multiple murine tumor models. The murine version of the immunoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Fallon, Jonathan K., Vandeveer, Amanda J., Schlom, Jeffrey, Greiner, John W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400526/
https://www.ncbi.nlm.nih.gov/pubmed/28423552
http://dx.doi.org/10.18632/oncotarget.16137

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400526/
https://www.ncbi.nlm.nih.gov/pubmed/28423552
http://dx.doi.org/10.18632/oncotarget.16137

Ejemplares similares